WAYNE, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led,
biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address
significant unmet needs in medical and aesthetic dermatology, today announced that, on March 5, 2018, the Compensation Committee of
Aclaris’ Board of Directors granted 3 non-qualified stock option awards to purchase an aggregate of 8,900 shares of its common
stock and 3 restricted stock unit awards covering an aggregate of 1,500 shares of its common stock to 3 new employees under
the Aclaris 2017 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the
new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
The 2017 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee
or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such
individual's entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
The options have an exercise price of $20.13 per share, which is equal to the closing price of Aclaris' common stock on March 5,
2018. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of
the shares on each of the first, second, third and fourth anniversaries of the recipient's start date, subject to each such
employee's continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the
terms and conditions of Aclaris' 2017 Inducement Plan, and the terms and conditions of a stock option agreement or restricted stock
unit agreement, as applicable, covering the grant.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and
commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunodermatology.
The Company focuses on market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Wayne,
Pennsylvania. More information can be found by visiting the Aclaris website at www.aclaristx.com.
Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
mtung@aclaristx.com
